---
title: "Humana reports mixed Q4 results; initiates FY25 outlook"
date: "2025-02-11 14:33:18"
summary: "Humana press release (NYSE:HUM): Q4 Non-GAAP EPS of -$2.16 misses by $0.04. Revenue of $29.21B (+10.4% Y/Y) beats by $370M. 4Q24 Insurance segment Adjusted benefit ratio of 91.9 percent, which includes a 20-basis point increase related to incremental Star Ratings investments, was consistent with expectations. Affirms previous commentary of Adjusted..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Humana [press release](https://seekingalpha.com/pr/19997666-humana-reports-fourth-quarter-2024-financial-results-provides-full-year-2025-financial) (NYSE:[HUM](https://seekingalpha.com/symbol/HUM "Humana Inc.")): Q4 Non-GAAP EPS of -$2.16  misses by $0.04.
* Revenue of $29.21B (+10.4% Y/Y)  beats by $370M.
* 4Q24 Insurance segment Adjusted benefit ratio of 91.9 percent, which includes a 20-basis point increase related to incremental Star Ratings investments, was consistent with expectations.
* Affirms previous commentary of Adjusted FY 2025 EPS guidance to be 'at least in line with 2024 results'; anticipating GAAP EPS of approximately $15.88, or approximately $16.25 on an Adjusted basis, inclusive of incremental investments to support operational excellence.
* Expects individual Medicare Advantage annual membership decline of approximately 550,000, or approximately 10 percent, from 2024, inclusive of the company's decision to exit certain unprofitable plans and counties.
* **FY 2025 Earnings Guidance**
  
  Humana provides its GAAP EPS guidance for the year ending December 31, 2025 (FY 2025) of approximately $15.88, or approximately $16.25 on an Adjusted basis.
  
  | Diluted earnings per share | FY 2025  Guidance | FY 2024 (a) |
  | --- | --- | --- |
  | GAAP | approximately$15.88 | $9.98 |
  | Amortization associated with identifiable intangibles | 0.49 | 0.50 |
  | Put/call valuation adjustments associated with the company's non-consolidating minority interest investments | — | 2.45 |
  | Impact of exit of employer group commercial medical products business | — | 1.19 |
  | Value creation initiatives | — | 2.33 |
  | Impairment charges | — | 1.65 |
  | Cumulative net tax impact of non-GAAP adjustments | (0.12) | (1.89) |
  | Adjusted (non-GAAP) – FY 2025 projected (b); FY 2024 Reported | approximately$16.25 **vs. consensus of $16.91** | $16.21 |

[seekalpha](https://seekingalpha.com/news/4406005-humana-reports-mixed-q4-results-initiates-fy25-outlook)
